NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Breakthrough Therapy designation for pain associated with DPN granted by FDA
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Global Phase-3 study initiation expected in the second half of 2024
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
A game changing solution for the pharmaceutical industry
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Subscribe To Our Newsletter & Stay Updated
